Titration of Dosage for the Protective Effect of Zoledronic Acid on Bone Loss in Patients Submitted to Androgen Deprivation Therapy due to Prostate Cancer: A Prospective Open-Label Study

Publisher： Karger

E-ISSN： 1423-0399|85|2|180-185

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.85, Iss.2, 2010-07, pp. : 180-185

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment

By  

Urologia Internationalis, Vol. 98, Iss. 1, 2016-09 ,pp. : 79-84

Karger

Access to resources Recommend Favorite

Prevention of Bone Mineral Loss by Zoledronic Acid in Men with Prostate Carcinoma Receiving Androgen Deprivation Therapy: A Prospective Randomized Trial in an Indian Population

By  

Current Urology, Vol. 2, Iss. 2, 2008-11 ,pp. : 79-86

Karger

Access to resources Recommend Favorite

Prospective Study of Estramustine Phosphate for Hormone Refractory Prostate Cancer Patients following Androgen Deprivation Therapy

By  

Urologia Internationalis, Vol. 75, Iss. 1, 2005-07 ,pp. : 43-49

Karger

Access to resources Recommend Favorite

Prospective memory in patients with prostate cancer

By  

EUROPEAN JOURNAL OF CANCER CARE (ELECTRONIC), Vol. 24, Iss. 2, 2015-03 ,pp. : 198-204

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Protective Effect of Zoledronic Acid on Bone Loss in Postmenopausal Women with Early Breast Cancer Treated with Sequential Tamoxifen and Letrozole: A Prospective, Randomized, Phase II Trial

By  

Oncology, Vol. 81, Iss. 5-6, 2011-12 ,pp. : 298-305

Karger

Access to resources Recommend Favorite